Skip to main content
Gansu Longshenrongfa Pharmaceutical Industry CO. ,LTD logo

Gansu Longshenrongfa Pharmaceutical Industry CO. ,LTD — Investor Relations & Filings

Ticker · 300534 ISIN · CNE100002CP5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,291 across all filing types
Latest filing 2026-05-15 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 300534

About Gansu Longshenrongfa Pharmaceutical Industry CO. ,LTD

https://www.lsrfzy.com

Gansu Longshenrongfa Pharmaceutical Industry CO., LTD. focuses on the research, development, production, and distribution of proprietary medicinal formulations. The company specializes in modernizing traditional herbal treatments, offering a diverse portfolio that includes tablets, capsules, and granules. Key therapeutic areas addressed by its product line encompass respiratory health, cardiovascular support, and digestive wellness. A primary offering is the Xuanfei Zhike granule, utilized for managing cough and respiratory symptoms. The organization integrates advanced manufacturing technologies with standardized quality control processes to ensure the consistency and efficacy of its products. By leveraging specialized botanical resources, the firm develops integrated solutions ranging from raw material processing to the commercialization of finished pharmaceutical preparations for various clinical applications.

Recent filings

Filing Released Lang Actions
2025年度分红派息实施公告
Notice of Dividend Amount Classification · 98% confidence The document is an official announcement detailing the company’s 2025 profit distribution (dividend) plan: per-share cash dividend amount, record date, ex-dividend date, payment method, and relevant tax treatment. It is not presenting full financial statements or wider annual results, nor is it a management report or call transcript. It clearly matches the definition of a Notice of Dividend Amount (DIV).
2026-05-15 Chinese
2025年度内部控制审计报告
Regulatory Filings
2026-04-02 Chinese
2025年度董事会工作报告
Board/Management Information Classification · 95% confidence The document is titled as the "2025年度董事会工作报告" (2025 Annual Board of Directors Work Report) of 甘肃陇神戎发药业股份有限公司. It details the board's activities, including production, marketing, innovation, governance, and plans for 2026. It is a comprehensive report on the board's work and governance over the year, not just an announcement or a brief summary. The content focuses on board activities, governance, and management oversight rather than full financial statements or audit results. This aligns with the category of Board/Management Information (MANG), which covers announcements of changes or reports on board and senior management activities. The document is over 6,700 characters, indicating it is a full report rather than a brief announcement. Therefore, the best classification is MANG with high confidence.
2026-04-02 Chinese
2025年度独立董事述职报告（罗臻）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2025 from 甘肃陇神戎发药业股份有限公司. It details the independent director's personal background, independence statement, attendance and participation in board and shareholder meetings, committee work, communication with auditors, focus on related party transactions, internal control and audit matters, nomination and appointment of directors and senior management, and overall evaluation and suggestions. The content is a detailed narrative of the independent director's duties and activities over the year, which is typical of an independent director's annual report or statement. It is not a full annual report (10-K), audit report, or earnings release. It is also not a proxy statement or voting results announcement. The document length is 4439 characters, which is relatively short but contains substantive content about the independent director's work rather than just an announcement. This type of document fits best under the category of "Board/Management Information (MANG)" as it relates to board member activities and governance reporting by a director. Therefore, the classification is MANG with high confidence.
2026-04-02 Chinese
未来股东回报规划（2026年—2028年）
Governance Information Classification · 95% confidence The document is a detailed plan regarding the company's future shareholder return policy for the years 2026 to 2028. It discusses profit distribution methods, cash dividends, stock dividends, decision-making procedures, and supervisory mechanisms. It is issued by the company's board of directors and is focused on outlining a policy framework rather than reporting actual financial results or earnings. The document length is 3233 characters, which is relatively short but contains substantive policy content rather than just an announcement or a brief summary. It is not an earnings release, annual report, or interim report, nor is it a regulatory filing or announcement of a report. It is a formal policy document issued by the board concerning shareholder returns and dividend policy. This fits best under the category of a Governance Information report (CGR), which covers internal rules, board structure, and governance practices including dividend and shareholder return policies.
2026-04-02 Chinese
关于2026年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the company's expected related party transactions for the fiscal year 2026. It includes extensive information about the types and amounts of transactions with related parties, the approval process by the board and independent directors, descriptions of related parties, and explanations of the transaction pricing and impact on the company. The document is not a financial report like an annual or interim report, nor is it a call transcript, audit report, or earnings release. It is a regulatory announcement about related party transactions, which is a common type of regulatory filing in Chinese listed companies. The document is lengthy (over 11,000 characters) and contains substantive content about the transactions, but it is not a financial statement or management discussion. It fits best under the category of Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-04-02 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.